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Abstract
Background and Objective Data from two similarly
designed studies of tapentadol extended release (ER) for
managing neuropathic pain associated with diabetic periphe-
ral neuropathy (DPN; NCT00455520, NCT01041859) in
adults were pooled for this analysis, allowing a detailed
evaluation of efficacy in patient subgroups and secondary
endpoints.
Methods In each study, patients were titrated to their
optimal dose of open-label tapentadol ER [100–250 mg
twice daily (bid)] over 3 weeks. Patients with C1-point
improvement in average pain intensity [11-point numerical
rating scale (NRS)] were randomized (1:1) to receive pla-
cebo or tapentadol ER during a 12-week, double-blind
maintenance period.
Results Mean (standard deviation [SD]) changes in pain
intensity from baseline to week 12 of maintenance in the
placebo (n = 343) and tapentadol ER (n = 360) groups,
respectively, were 1.28 (2.41) and 0.08 (1.87) [least
squares mean difference (LSMD): -1.14 (95 % confi-
dence interval [CI]: -1.435, -0.838); P \ 0.001, in
favour of tapentadol ER]. Significant between-group dif-
ferences were also observed in changes from the start of
the double-blind treatment period to the double-blind
endpoint for the Short Form-36 physical functioning,
role-physical, bodily pain, social functioning and role-
emotional subscale and physical component summary
scores, and the EuroQol 5-Dimension health status index
(all P \ 0.05, in favour of tapentadol ER). No clinically
relevant differences were observed in the efficacy of ta-
pentadol ER across patient subgroups divided by age, sex,
race, opioid experience and pain intensity. Incidences of
treatment-emergent adverse events were 56.0 % (192/343)
with placebo and 74.7 % (269/360) with tapentadol ER
during maintenance.
Conclusion Results of this pooled analysis indicate that
tapentadol ER was effective for managing DPN-related
pain, and provided consistent analgesic efficacy across
different patient subgroups.
Previous presentation: Results of this analysis have been
previously presented, in part, at the American Diabetes Association
72nd Scientific Sessions; June 8–12, 2012; Philadelphia, PA, USA.
ClinicalTrials.gov Identifiers: NCT00455520 and NCT01041859.
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Key Points
Results of this pooled analysis indicate that
tapentadol extended release (ER) is effective and
well tolerated for the management of neuropathic
pain associated with diabetic peripheral neuropathy
(DPN) in adults.
Tapentadol ER is associated with improvements in
measures of health-related quality of life in patients
with painful DPN.
Tapentadol ER provides consistent efficacy across
different patient subgroups divided by age, sex, race,
opioid experience and pain intensity.
1 Introduction
Painful diabetic peripheral neuropathy (DPN) is a common
complication of diabetes [1, 2], affecting an estimated
10–26 % of diabetic patients [2, 3]. Symptoms of painful
DPN may include burning pain, pain radiating down the
legs, stabbing pains, paraesthesia and allodynia [2]. Painful
DPN is often very distressing for patients, and may be
associated with a reduction in physical functioning, poor
sleep quality and an increased risk of anxiety or depression
[2–5].
Although the pathophysiology of painful DPN is not
fully understood [1], both central and peripheral mecha-
nisms are likely involved in the genesis of pain [2, 3, 6],
which complicates the management of patients with painful
DPN [1, 2]. Duloxetine and pregabalin, which are approved
by the US Food and Drug Administration (FDA) for the
management of painful DPN, have generally been con-
sidered first-line treatment options for pain related to DPN
[7].
Although opioid analgesics (e.g. morphine, oxycodone)
have been shown to be efficacious for the management of
neuropathic pain, they have generally been considered
second-line treatments because of the potential for tolera-
bility and safety issues, the development of physical
dependency and the risk of abuse or misuse with long-term
therapy [2, 7, 8]. Long-term opioid therapy may be asso-
ciated with hypogonadism, suppressed immune functioning
or various side effects, such as constipation, nausea and
sedation [8]. Nausea and sedation generally resolve with
time and can often be avoided by the use of low starting
doses and slow up-titration [8]. Opioid-induced constipa-
tion is often chronic [8] and may require reduction or
discontinuation of opioids or switching to an alternative
therapy for pain [9, 10]. Because single pharmacological
agents may provide insufficient relief for painful DPN,
combinations of two or more drugs with different mecha-
nisms of action are considered as an option for patients
who fail to achieve adequate analgesia with a single
treatment [2, 8].
Tapentadol represents a proposed new class of centrally
acting analgesic combining two mechanisms of action,
l-opioid receptor agonism and norepinephrine reuptake
inhibition [11]. The norepinephrine reuptake inhibitor
activity of tapentadol may contribute to an opioid-sparing
effect [11], resulting in the improved gastrointestinal tol-
erability compared with traditional opioid analgesics
(controlled-release morphine and oxycodone) that has been
demonstrated in phase 3 studies of an extended-release
formulation of tapentadol [12–17]. Tapentadol extended
release [ER; prolonged release (PR) in Europe] has been
shown to be effective and well tolerated for the manage-
ment of moderate to severe chronic pain in randomized,
double-blind, placebo- and/or active-controlled phase 3
studies [12–14, 18, 19]. Results of two of these studies
[randomized-withdrawal, multicentre, placebo-controlled,
phase 3 trials (ClinicalTrials.gov Identifiers:
NCT00455520 [18] and NCT01041859 [19]), which had a
similar design] demonstrated that tapentadol ER
[100–250 mg twice daily (bid)] is efficacious and well
tolerated in patients with moderate to severe, chronic,
painful DPN. In August of 2012, tapentadol ER received
FDA approval for the management of neuropathic pain
associated with DPN in adults when a continuous, around-
the-clock opioid analgesic is needed for an extended period
of time. Both studies [18, 19], upon which FDA approval
was based, were powered with sample sizes to evaluate the
primary endpoint. Neither study [18, 19] was powered to
allow for subgroup analyses or the analyses of secondary
endpoints. The objective of the present post hoc analysis
was to evaluate data pooled from those two studies [18, 19]
to allow for a more detailed evaluation of efficacy in dif-
ferent patient subgroups and of secondary efficacy and
quality-of-life endpoints.
2 Patients and Methods
2.1 Patient Population and Disallowed Concomitant
Medications
In the two studies included in this pooled analysis, eligible
patients were adults at least 18 years of age with a diag-
nosis of type 1 or 2 diabetes mellitus and painful DPN, with
signs and symptoms present for at least 6 months prior to
screening and pain present at the time of screening.
Patients were required to have their diabetes well
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controlled by diet, oral hypoglycaemic agents or insulin for
a minimum of 3 months prior to study enrolment. In the
first study [18], adequate blood glucose control must have
been demonstrated by a glycated haemoglobin (HbA1c)
level of no more than 11 % for at least 3 months prior to
enrolment. In the second study [19], adequate blood glu-
cose control was demonstrated by a stable, optimized
diabetic regimen (consisting of diet, oral hypoglycaemic
therapy or insulin therapy) for at least 3 months prior to
enrolment. Patients must have been taking an analgesic
medication for their painful DPN for at least 3 months
prior to screening; for patients taking an opioid, the dose
equivalent of oral morphine must have been no more than
160 mg/day. Patients taking opioid analgesics must have
been dissatisfied with their treatment (in terms of pain
relief or tolerability), while patients taking non-opioid
analgesics must have been dissatisfied with their current
level of pain relief. Patients were required to have a mean
pain intensity score of at least 5 on an 11-point numerical
rating scale (NRS; 0 = ‘‘no pain’’ to 10 = ‘‘pain as bad as
you can imagine’’); the mean pain intensity score for this
inclusion criterion was based on twice-daily pain intensity
assessments (patient-rated average pain levels over the past
12 h) that were recorded during a 3-day evaluation period
prior to the start of open-label treatment.
In both studies, patients were excluded if they had
participated in another trial within 30 days of enrolment
or if they had participated in another tapentadol trial.
Patients were also excluded if they had a history of
alcohol or drug abuse or were known or suspected to be
unable to comply with the study protocol and use of the
study drug. Additional exclusion criteria common to both
studies included significant pulmonary, gastrointestinal,
metabolic (except diabetes mellitus), neurological, psy-
chiatric or other disorders that could affect efficacy or
safety assessments or compromise patient safety; signifi-
cant cardiac or vascular disease; a history of seizure
disorder or epilepsy; a history of mild or moderate trau-
matic brain injury, stroke, transient ischaemic attack or
brain neoplasm within 1 year; a history of severe trau-
matic brain injury within 15 years; a history of malig-
nancy within the past 2 years (except for successfully
treated basal cell carcinoma); severe renal impairment;
moderate or severe hepatic impairment; chronic hepatitis
B or C; active hepatitis B or C within the past 3 months;
severe or extensive diabetic foot ulcers, limb amputation,
or Charcot neuroarthropathy; a clinically relevant history
of sensitivity to acetaminophen or opioid analgesics (or
their ingredients); any scheduled surgery or painful pro-
cedure during the study that could affect efficacy or safety
assessments; and any condition (other than painful DPN)
that could confound the assessment or self-evaluation of
pain (e.g. fibromyalgia, rheumatoid arthritis, ankylosing
spondylitis [6]). Women who were pregnant or breast-
feeding were also excluded from both studies.
The use of other analgesics, besides permitted doses of
acetaminophen and tapentadol ER (as described in the
‘Study Design’ section), was not permitted during either
study. In both studies, the use of neuroleptics, monoamine
oxidase inhibitors, serotonin norepinephrine reuptake
inhibitors (SNRIs), tricyclic antidepressants, anticonvul-
sants and antiparkinsonian drugs was prohibited within
14 days of screening and throughout the study, and the use
of corticosteroids (other than topical or inhaled steroids)
was prohibited within 4 weeks to 6 months of screening
(depending on the method of administration) and
throughout the study. Neuroleptics, SNRIs, anticonvulsants
and antiparkinsonian drugs were not permitted because of
the potential that their use could confound analgesic effi-
cacy assessments. Selective serotonin reuptake inhibitors
were permitted if patients were taking a stable dose for at
least 3 months prior to screening.
2.2 Study Design
Both studies had similar randomized-withdrawal, double-
blind, placebo-controlled designs. The first study [18] used
the conventional hypromellose-based formulation
employed in other phase 3 clinical trials [12, 13, 20], while
the second study [19] used a new formulation of tapentadol
ER that has a high mechanical strength resulting from a
polyethylene oxide matrix and melt extrusion manufac-
turing process, is less susceptible to crushing or extraction
than the conventional hypromellose-based formulation and
is intended to reduce the potential for tampering with the
tablet that might overcome the extended-release charac-
teristics. The new formulation of tapentadol ER, which has
a similar release profile to the hypromellose-based formu-
lation [21], has been approved for the management of
chronic pain in the United States.
The initial open-label phase of both studies included
a screening period, a washout period, a pre-titration pain
intensity evaluation period and an open-label titration
period. During the washout period (typically 3–14 days
in the first study [18] and 5 days in the second study
[19]), patients discontinued all prior medications that
were being taken to manage painful DPN. In both
studies [18, 19], any medication that was being taken to
manage pain related to DPN was to be washed out for at
least five times the elimination half-life of that medi-
cation prior to starting open-label treatment. In the first
study [18], eligible patients taking SNRIs, anticonvul-
sants or tricyclic antidepressants, solely for pain related
to DPN and not for other disorders, could proceed to
washout immediately after signing the informed consent
document, such that washout could extend through the
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combined screening and washout period (14 days). If
patients in that study [18] were taking a drug with an
extended elimination half-life (e.g. methadone) for their
painful DPN, the washout period could be extended
beyond 14 days. For the second study [19], the screen-
ing and washout periods could be combined (total,
18 days) if more than 5 days of washout was required to
allow for a washout period of at least five half-lives of a
medication. The washout period was followed by a
3-day, pre-titration pain intensity evaluation period to
determine eligibility to enter the study; patients with a
pre-titration mean pain intensity score of at least 5
then entered a 3-week, open-label titration period [pre-
titration mean pain intensity score was calculated from
the average daily pain intensity scores during that 3-day
period, with average daily pain intensity based on twice-
daily pain intensity assessments (morning and evening)].
During the open-label titration period, all patients ini-
tially received tapentadol ER 50 mg bid for 3 days, then
the dose was increased to 100 mg bid. Doses could be
titrated upwards in increments of 50 mg bid every
3 days (to a maximum dose of 250 mg bid) or down-
ward in decrements of 50 mg bid without a time
restriction (to a minimum dose of 100 mg bid) for the
remainder of this period. The purpose of titration was to
allow each patient to reach a dose of tapentadol ER that
provided an optimal balance of pain reduction and tol-
erability. Throughout the titration period (except during
the last 4 days to allow for evaluation of baseline pain
intensity, as described in Sect. 2.3), acetaminophen
(B2,000 mg/day) was permitted as additional analgesia.
Patients who tolerated tapentadol ER and had at least a
1-point improvement in average pain intensity from the
pre-titration evaluation period to the last 3 days of the
titration period were randomized (1:1) to receive placebo
or tapentadol ER during a 12-week, double-blind main-
tenance period. To minimize the possibility of withdrawal
symptoms, patients who were randomized to placebo
received blinded tapentadol ER 100 mg bid for 3 days
before switching to placebo twice daily from day 4 of the
maintenance period onwards. Patients who were ran-
domized to tapentadol ER continued taking the same
optimal dose of tapentadol ER that was determined during
the open-label titration period. Patients in both treatment
groups were allowed to take supplemental tapentadol ER
25 mg bid as additional analgesia during the first 4 days
of the maintenance period; from day 5 of the maintenance
period onwards, patients were permitted to take a sup-
plemental dose of tapentadol ER 25 mg once daily. At
approximately 4 days after the last intake of study drug, a
follow-up clinic visit was scheduled and, at approximately
10–14 days after the last intake of study drug, a follow-up
phone call was scheduled.
2.3 Efficacy Evaluations
Patients recorded their average pain intensity (11-point
NRS) over the past 12 hours twice daily during the 3-day,
pre-titration pain intensity evaluation period and through-
out the titration and maintenance periods. Daily pain
intensity was defined as the mean of the average pain
intensity scores in a 24-h period. Baseline pain intensity
was defined as the mean of the average daily pain intensity
scores during the last 3 days prior to randomization (i.e. the
last 3 days of the open-label titration period). The baseline
score was based on the mean of average daily pain intensity
scores for the last 3 days of the titration period to reflect
pain intensity on the final optimal dose of tapentadol ER
that was determined during the titration period. Weekly
average pain intensities during the double-blind treatment
period were defined as the means of the average daily pain
intensities in each 7-day period starting from the first dose
of double-blind study drug. The primary efficacy endpoint
was the mean change in average pain intensity (11-point
NRS) from baseline to week 12 (mean of seven daily
average pain intensity scores during week 12) of the dou-
ble-blind maintenance period. Secondary efficacy end-
points included the following: responder rates (based on
the percentage improvement in pain intensity from pre-
titration) at week 12 of the maintenance period; the Patient
Global Impression of Change (PGIC) [22, 23] at the dou-
ble-blind endpoint; and changes in the Brief Pain Inven-
tory—Short Form (BPI-SF) [24] pain interference and pain
intensity subscale scores, Short Form-36 (SF-36) Health
Survey [25] subscales and summary scales and EuroQol
5-Dimension (EQ-5D) health status index [26] from the
start of the double-blind maintenance period to the double-
blind endpoint.
For the responder rate analysis, the number and per-
centage of patients achieving at least a 30 % improvement
in pain intensity and at least a 50 % improvement in pain
intensity from pre-titration to week 12 of the double-blind
maintenance period were evaluated by treatment group.
The percentage change in pain intensity from pre-titration
to week 12 of the double-blind maintenance period was
calculated as follows: 100 9 (average pain intensity during
week 12 - average pre-titration pain intensity)/(average
pre-titration pain intensity). Patients who discontinued
during treatment, had pain intensity that worsened or had
no change in pain intensity were considered to be non-
responders. For the PGIC [22, 23], patients rated the
change in their overall status since beginning study treat-
ment on a scale from 1 (‘‘very much improved’’) to 7
(‘‘very much worse’’). The BPI-SF [24] was used to assess
the pain severity and interference with daily activity. The
BPI-SF includes one item evaluating the level of pain relief
over the past 24 hours (scored from 0 % = ‘‘no relief’’ to
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100 % = ‘‘complete relief’’); four items evaluating the
pain intensity (11-point NRS) at the time the questionnaire
was completed, at its worst, at its least and on average over
the previous week; and seven items evaluating pain inter-
ference with mood, walking, other physical activity, work,
social activity, relations with others and sleep (each rated
on an 11-point scale; 0 = ‘‘does not interfere’’ to
10 = ‘‘completely interferes’’). Scores for the individual
items of the BPI-SF were combined to yield pain severity
and pain interference subscales. The SF-36 [25] health
status survey includes physical functioning, role-physical,
bodily pain, general health, vitality, social functioning,
role-emotional and mental health subscales; each subscale
was scored from 0 (‘‘poor health’’) to 100 (‘‘good health’’).
Weighted combinations of the eight subscale scores were
used to derive two summary scores, the mental and phys-
ical component summary scores. The EQ-5D [26] mea-
sures five dimensions of health status (mobility, self-care,
usual activities, pain or discomfort, and anxiety or
depression); each dimension was scored using one of three
possible responses (‘‘no problems,’’ ‘‘some problems’’ or
‘‘extreme problems’’). An overall EQ-5D health status
index score (possible score, 0 = ‘‘death’’ to 1 = ‘‘full
health’’) was obtained from a combination of responses to
the individual dimensions, which were scored using a
utility-weighted algorithm.
For the primary efficacy outcome (average pain intensity
on an 11-point NRS), subgroup analyses were performed
on the basis of sex, age group (C65 vs \65 years), race
(white, black and other), prior opioid experience (opioid
naive vs opioid experienced) and pain intensity category at
the start of the double-blind maintenance period (11-point
NRS; none, 0; mild,[0 to\4; moderate, C4 to\6; severe,
C6). Opioid-experienced patients were defined as those
patients who had previously received an opioid analgesic
for the treatment of painful DPN for at least 3 weeks
continuously or intermittently, regardless of their response
to treatment.
2.4 Safety and Tolerability Evaluations
Treatment discontinuations and treatment-emergent
adverse events (TEAEs) were monitored and recorded
throughout both studies. For each treatment period (the
open-label titration period and the double-blind treatment
period), a TEAE was defined as any adverse event that
newly occurred or worsened in intensity after the first
intake of study drug during that period. All TEAEs were
coded using the Medical Dictionary for Regulatory Activ-
ities (MedDRA), version 13.1. HbA1c levels, which served
as a marker of glycaemic control, were measured at
screening and at the end of treatment or at early withdrawal
in both studies. Other safety evaluations performed in both
studies included additional laboratory tests, physical
examinations (including a standard neurological examina-
tion), vital sign measurements and electrocardiograms; the
results of these evaluations were not pooled and will not be
presented here.
2.5 Statistical Analyses
The intent-to-treat (ITT) populations were used for efficacy
evaluations. The open-label ITT and safety populations of
each study included all patients who received at least one
dose of study drug during the open-label titration period.
The double-blind ITT and safety populations of each study
included all randomized patients who received at least one
dose of study drug during the double-blind maintenance
period.
The last observation carried forward (LOCF) was used
for imputing missing pain intensity assessments for the
analysis of the primary efficacy endpoint. The primary
efficacy endpoint was analysed using an analysis of
covariance (ANCOVA) model similar to that used in the
individual studies [18, 19], which included treatment,
study, country and dose category at the end of the open-
label titration period (low dose, 100–150 mg bid; high
dose, 200–250 mg bid) as factors and mean pain intensity
at the start of the double-blind maintenance period as a
covariate. Treatment effects were estimated on the basis of
the least squares mean difference (LSMD) in the change
from baseline to week 12 of the double-blind maintenance
period. The test for efficacy analysis was two-sided at the
0.05 level of significance.
Exploratory sensitivity analyses of the primary efficacy
endpoint were performed using alternative imputation
methods, including baseline observation carried forward
(BOCF), worst observation carried forward (WOCF), pla-
cebo mean imputation (PMI) and modified BOCF (as
described previously for the first DPN study [18]). In
addition, an observed-case analysis was performed for the
primary efficacy endpoint. As a post hoc sensitivity ana-
lysis, a longitudinal evaluation of the change in average
pain intensity from baseline to week 12 of the double-blind
maintenance period, including all observed data, was per-
formed using a mixed-effects model for repeated measures
(MMRM), including treatment, week, treatment-by-week
interaction, country and dose level at baseline as factors
and baseline average pain intensity score as a covariate.
The distribution of responder rates at week 12 of the
maintenance period was evaluated using a Kaplan–Meier
estimate, and between-group comparisons were performed
using a log-rank test. The numbers and percentages of
patients with at least a 30 % and at least a 50 %
improvement in pain intensity from pre-titration to week 12
of the maintenance period were evaluated for each
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treatment group. The numbers and percentages of patients
were also summarized by treatment group for PGIC
assessments at the double-blind endpoint. Between-group
comparisons for the percentages of patients with at least a
30 % and at least a 50 % improvement in pain intensity
and PGIC evaluations were performed using a Cochran–
Mantel–Haenszel test, controlling for treatment, study,
country and dose category at the end of the open-label
titration period.
The absolute values and changes from the start of the
double-blind maintenance period to the double-blind end-
point in the BPI-SF pain intensity and pain interference
subscale scores, SF-36 subscale and summary scores, and
EQ-5D health status index were summarized using
descriptive statistics. Between-group comparisons of the
changes from the start of the double-blind maintenance
period to the double-blind endpoint in these measures were
analysed using the same ANCOVA model as defined for
the primary efficacy endpoint.
For subgroup analyses of the change in average pain
intensity (11-point NRS) from baseline to week 12 of the
double-blind maintenance period, results for the subgroups
were summarized if at least 10 % of the total number of
patients were in at least two of the subgroups. An
ANCOVA model similar to that used for the primary
efficacy analysis was used to evaluate differences between
the tapentadol ER and placebo groups in the change in
average pain intensity from baseline to week 12 of the
double-blind maintenance period for each of the subgroups
(divided according to sex, age, race, prior opioid experi-
ence and pain intensity category at the start of the double-
blind maintenance period, as described previously).
Incidences of all reported TEAEs during the double-
blind maintenance period were summarized descriptively.
Changes in HbA1c levels were evaluated from the start of
the open-label titration period to endpoint of the open-label
titration period for patients who discontinued treatment
during the open-label titration period, and from the start of
the open-label titration period to endpoint of the double-
blind maintenance period for patients who entered the
double-blind maintenance period. The endpoint values for
efficacy and safety measures during the open-label titration
period and double-blind maintenance period were defined
as the last available measures during the respective period.
3 Results
3.1 Patients
Across the two studies included in this analysis, 1,040
patients received treatment during the open-label titration
period and 703 patients received treatment during the
double-blind maintenance period. Of the patients who were
treated in the open-label titration period, the percentage
who failed to meet the randomization criterion (C1-point
improvement in pain intensity) was low (5.0 %
[52/1,040]). For the double-blind safety population,
demographic and baseline characteristics were similar
across the placebo and tapentadol ER treatment groups
(Table 1). In the double-blind ITT population (n = 703),
59.7 % of patients were male, 74.8 % of patients were
white, 69.3 % of patients were under 65 years of age and
66.9 % of patients were opioid naive. The majority of
patients (83.9 % [587/700]) in the double-blind ITT pop-
ulation with available pain intensity scores had severe pain
intensity (C6 on an 11-point NRS) at the start of the open-
label titration period, while more than half of the patients
(57.3 % [400/698]) had no pain or mild pain intensity (\4
on an 11-point NRS) at the start of the double-blind
maintenance period.
During the open-label titration period, 28.5 % of
patients (296/1,040) discontinued treatment; the most
common reason for treatment discontinuation during titra-
tion was adverse events (16.3 % [169/1,040]; Table 2).
During the double-blind maintenance period, 30.0 % of
patients (103/343) in the placebo group and 28.9 % of
patients (104/360) in the tapentadol ER group discontinued
treatment. In the placebo and tapentadol ER groups, the
most common reasons for treatment discontinuation were a
lack of efficacy (placebo, 11.1 % [38/343]; tapentadol ER,
3.1 % [11/360]) and adverse events (placebo, 8.2 %
[28/343]; tapentadol ER, 14.2 % [51/360]; Table 2).
3.2 Treatment Exposure
The median duration of treatment exposure during the
double-blind maintenance period was 84 days in both the
placebo and tapentadol ER groups. The majority of patients
in both treatment groups (placebo, 71.4 % [245/343]; ta-
pentadol ER, 71.7 % [258/360]) received double-blind
treatment for 71 days or more.
At the end of the open-label titration period, almost half
of patients (48.4 % [340/703]) were taking tapentadol ER
250 mg bid. The median modal total daily dose of ta-
pentadol ER was 300 mg during the open-label titration
period and 400 mg during the double-blind maintenance
period. There was no notable increase in the mean total
daily dose of tapentadol ER during the double-blind
maintenance period (start of double-blind maintenance,
391.3 mg; week 12 of double-blind maintenance,
393.6 mg). During the double-blind maintenance period,
57.4 % of patients (197/343) in the placebo group and
50.8 % of patients (183/360) in the tapentadol ER group
took supplemental tapentadol ER. The mean percentage of
days that patients in the placebo group took supplemental
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tapentadol ER was higher than in the tapentadol ER group
(47.8 % and 31.8 %, respectively).
3.3 Efficacy
Mean (standard error) pain intensity scores over the course
of the study are shown in Fig. 1. For the open-label ITT
population, mean [standard deviation (SD)] pain intensity
(observed-case analysis) was 7.29 (1.38) at the start of the
open-label titration period and 4.15 (2.10) at week 3 of the
open-label titration period; the mean change from the start
to week 3 of the open-label titration period was -3.19
(2.00). For patients who tolerated tapentadol ER, had at
least a 1-point improvement in pain intensity during the
open-label titration period and were randomized to treat-
ment in the double-blind maintenance period, mean (SD)
pain intensity scores (LOCF) were 3.48 (2.02) in the pla-
cebo group and 3.67 (1.84) in the tapentadol ER group at
Table 1 Demographic and baseline characteristics [double-blind (DB) intent-to-treat (ITT) population]
Characteristic Placebo (n = 343) Tapentadol ER (n = 360)
Sex, n (%)
Male 202 (58.9) 218 (60.6)
Female 141 (41.1) 142 (39.4)
Race, n (%)a
White 253 (73.8) 273 (75.8)
Black 41 (12.0) 49 (13.6)
Asian 3 (0.9) 4 (1.1)
American Indian or Alaskan Native 3 (0.9) 3 (0.8)
Other 43 (12.5) 31 (8.6)
Mean (SD) age, years 59.9 (9.94) 59.1 (10.62)
Age category (years)
\65 229 (66.8) 258 (71.7)
C65 114 (33.2) 102 (28.3)
Prior opioid experience, n (%)b
Opioid naive 229 (66.8) 241 (66.9)
Opioid experienced 114 (33.2) 119 (33.1)
Mean (SD) duration of DPN, yearsc 6.1 (5.41) 5.3 (4.81)
Mean (SD) start OL pain intensity scored,e 7.4 (1.29) 7.3 (1.41)
Start OL pain intensity category, n (%)f
Mild 0 2 (0.6)
Moderate 44 (12.9) 67 (18.7)
Severe 298 (87.1) 289 (80.7)
Mean (SD) start DB pain intensity scoreg,h 3.5 (2.02) 3.7 (1.84)
Start DB pain intensity category, n (%)a,f
None 10 (2.9) 5 (1.4)
Mild 196 (57.3) 189 (53.1)
Moderate 88 (25.7) 117 (32.9)
Severe 48 (14.0) 45 (12.6)
DPN diabetic peripheral neuropathy, ER extended release, NRS numerical rating scale, OL open-label, SD standard deviation
a Percentages may not total 100 % because of rounding
b Opioid experience was defined as having previously received an opioid analgesic for the treatment of painful DPN for C3 weeks continuously
or intermittently, regardless of the response to treatment
c Placebo, n = 212; tapentadol ER, n = 225
d Start OL pain intensity score is the average of pain scores over the 3 days prior to start of titration
e Placebo, n = 342; tapentadol ER, n = 358
f Pain intensity categories: none, 0; mild,[0 to\4; moderate, C4 to\6; severe, C6 on an 11-point NRS (0 = ‘‘no pain’’ to 10 = ‘‘pain as bad as
you can imagine’’)
g Start DB pain intensity score is the average of pain scores over the 72 h prior to randomization
h Placebo, n = 342; tapentadol ER, n = 356
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baseline (average pain over the 3 days prior to the start of
the double-blind maintenance period), and 4.76 (2.52) in
the placebo group and 3.77 (2.19) in the tapentadol ER
group at week 12 of the double-blind maintenance period.
The mean (SD) change from baseline to week 12 of the
maintenance period was 1.28 (2.41) in the placebo group
and 0.08 (1.87) in the tapentadol ER group [LSMD for
tapentadol ER vs placebo (95 % confidence interval [CI])
-1.14 (-1.435, -0.838); P \ 0.001]. These results
indicate that pain intensity worsened upon switching from
open-label tapentadol ER treatment to placebo during the
double-blind maintenance period but was relatively
unchanged with continued treatment with tapentadol ER.
Sensitivity analyses using alternative imputation meth-
ods supported the results of the primary efficacy analysis.
Statistically significant differences were observed between
placebo and tapentadol ER for the change in average pain
intensity from baseline to week 12 of the double-blind
maintenance period, using all alternative imputation
methods (P \ 0.001, in favour of tapentadol ER for all
comparisons; Fig. 2). The results of the post hoc MMRM
analysis were consistent with those of the primary efficacy
analysis using LOCF and the other imputation methods
summarized in Fig. 2; using the MMRM, the estimated
difference between the tapentadol ER and placebo groups
for the change from baseline to week 12 of the double-
blind maintenance period was -1.14 (95 % CI -1.47,
-0.82; P \ 0.001).
A significant difference was observed in the overall
distribution of responder rates between the placebo and
tapentadol ER groups (P = 0.0167, in favour of tapentadol
ER). As shown in Fig. 3, the percentages of patients who
achieved at least a 30 % improvement and at least a 50 %
improvement in pain intensity from the start of the open-
label titration period to week 12 of the double-blind
maintenance period were significantly lower in the placebo
group than in the tapentadol ER group (both P B 0.005).
For the PGIC, a significant difference in the distribution
of PGIC scores was observed between the placebo and
tapentadol ER groups (P \ 0.001, in favour of tapentadol
ER). The percentage of patients who reported that their
overall status was ‘‘very much improved’’ or ‘‘much
improved’’ on the PGIC at the double-blind endpoint
was 41.7 % (131/314) in the placebo group and 65.5 %
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(Patients treated with either placebo or tapentadol ER)
Fig. 1 Mean [standard error (SE)] pain intensity over time [intent-to-
treat (ITT) population]. Values during the OL titration period are
based on observed-case analysis, and values during the DB mainte-
nance period are based on the last observation carried forward
(LOCF). Patients were required to have C1-point improvement in
pain intensity during the OL titration period to be eligible for
randomization to treatment during the DB maintenance period. BL
baseline, DB double-blind, ER extended release, OL open-label. aOL
tapentadol ER population: start OL, n = 1,034; week 1, n = 1,038;
week 2, n = 951; week 3, n = 869. bValue for week 3 of the OL
titration period is also shown at this timepoint
Table 2 Reasons for treatment discontinuation [intent-to-treat (ITT) population]
Reason for discontinuation, n (%) OL titration DB maintenance
Tapentadol ER (n = 1,040) Placebo (n = 343) Tapentadol ER (n = 360)
Total discontinuations for any reason 296 (28.5) 103 (30.0) 104 (28.9)
Adverse event 169 (16.3) 28 (8.2) 51 (14.2)
Withdrawal of consent 32 (3.1) 16 (4.7) 21 (5.8)
Ineligible for DB maintenance 26 (2.5) – –
Lack of efficacy 22 (2.1) 38 (11.1) 11 (3.1)
Study drug noncompliance 22 (2.1) 8 (2.3) 6 (1.7)
Lost to follow-up 5 (0.5) 2 (0.6) 2 (0.6)
Physician decision 1 (0.1) 1 (0.3) 2 (0.6)
Protocol violation 1 (0.1) 2 (0.6) 1 (0.3)
Other 18 (1.7) 8 (2.3) 10 (2.8)
DB double-blind, ER extended release, OL open-label
102 S. Schwartz et al.
mean (SD) changes in the pain intensity subscale score
from the start of the double-blind treatment period to the
double-blind endpoint were significantly different between
the placebo (1.0 [2.22]) and tapentadol ER groups (-0.0
[1.87]; P \ 0.001, in favour of tapentadol ER). A signifi-
cant difference was also observed in the mean (SD)
changes from the start of the double-blind treatment period
to the double-blind endpoint in the BPI-SF pain interfer-
ence subscale score between treatment groups (placebo, 0.7
[2.27]; tapentadol ER, -0.2 [1.79]; P \ 0.001, in favour of
tapentadol ER). For both BPI-SF subscales, mean scores
increased in the placebo group over the course of the
double-blind maintenance period, indicating that pain
intensity and pain interference worsened after the switch
from open-label tapentadol ER treatment to placebo, while
mean pain intensity and interference subscale scores were
unchanged or improved slightly with continued tapentadol
ER treatment.
For the SF-36 physical functioning, role-physical, bod-
ily pain, social functioning and role-emotional subscale
scores and the physical component summary score, sig-
nificant differences were observed in the changes from the
start of the double-blind treatment period to the double-
blind endpoint between the placebo and tapentadol ER
groups (P \ 0.05, in favour of tapentadol ER; Fig. 4). A
significant difference was also observed in the change from
the start of the double-blind treatment period to the double-
blind endpoint for the EQ-5D health status index between
the placebo and tapentadol ER groups (LSMD for tapent-
adol ER vs placebo [95 % CI], 0.09 [0.056, 0.122];
P \ 0.001), also in favour of tapentadol ER.
3.4 Subgroup Analyses
Slight differences were observed between patients grouped
according to age or race in the mean change in pain
intensity from baseline to week 12 of the maintenance
period between the placebo and tapentadol ER groups
(LSMD for tapentadol ER vs placebo: \65 years of age,
-1.18; C65 years of age, -1.01; black, -1.12; white,
-1.15; other, -1.05). Differences between the placebo and
tapentadol ER groups in the mean change in pain intensity





















P  vs placebo
Fig. 2 Sensitivity analyses of
the primary efficacy analysis
[double-blind (DB) intent-to-
treat (ITT) population]. BOCF
baseline observation carried
forward, CI confidence interval,
ER extended release, LOCF last
observation carried forward,

























Tapentadol ER (n = 360)Placebo (n = 342)
Fig. 3 Responder rates for a C30 % and a C50 % reduction in pain
intensity from the start of the open-label (OL) titration period to week
12 of the double-blind (DB) maintenance period [DB intent-to-treat
(ITT) population]. P B 0.005 for tapentadol extended release (ER)
versus placebo for both responder rates
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from baseline to week 12 of the maintenance period were
numerically greater for patients with mild pain intensity
(LSMD for tapentadol ER vs placebo: -1.25) than for
those with moderate pain intensity (-0.97) or severe pain
intensity (-0.82) at the start of the double-blind mainte-
nance period. A numerically greater difference was
observed in the mean change in pain intensity from base-
line to week 12 of the maintenance period between the
placebo and tapentadol ER groups for female patients
(LSMD for tapentadol ER vs placebo: -1.51) than for male
patients (-0.89), and for opioid-naive patients (-1.21)
than for opioid-experienced patients (-1.00). Although
numerical differences in the LSMD between the placebo
and tapentadol ER groups in the mean change in pain
intensity from baseline to week 12 of the maintenance
period were observed between subgroups of patients divi-
ded according to pain intensity at the start of the double-
blind maintenance period, sex and opioid experience, these
differences were not considered to be clinically relevant.
3.5 Safety and Tolerability
At least one TEAE was reported by 73.1 % of patients
(760/1,040) during the open-label titration period. Gastro-
intestinal TEAEs (40.7 % [423/1,040]), including nausea
and constipation, and nervous system TEAEs (38.7 %
[402/1,040]), including dizziness and somnolence, were
among the most commonly reported TEAEs during titra-
tion (Table 3).
During the double-blind maintenance period, 56.0 % of
patients (192/343) in the placebo group and 74.7 % of
patients (269/360) in the tapentadol ER group reported at
least one TEAE. Among the most common TEAEs in the
placebo and tapentadol ER groups were gastrointestinal
TEAEs (placebo, 17.8 % [61/343]; tapentadol ER, 34.7 %


















































































Tapentadol ER (n = 360)Placebo (n = 343)
Fig. 4 Mean change in Short Form-36 (SF-36) subscale and summary scale scores from the start of the double-blind (DB) treatment period to
the DB endpoint. Negative values indicate deterioration. ER extended release. *P \ 0.05 versus placebo. **P B 0.001 versus placebo
Table 3 Treatment-emergent adverse events (TEAEs) reported by
C5 % of patients during the open-label (OL) titration period (OL
safety population)a
TEAE, n (%) Tapentadol ER
(n = 1,040)




Dry mouth 67 (6.4)
Diarrhoea 47 (4.5)




General disorders and administration site conditions 156 (15.0)
Fatigue 84 (8.1)
Skin and subcutaneous tissue disorders 124 (11.9)
Pruritus 73 (7.0)
Metabolism and nutrition disorders 77 (7.4)
Decreased appetite 49 (4.7)
ER extended release
a Incidence is based on the number of patients experiencing C1
TEAE, not the number of TEAEs
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system TEAEs (placebo, 12.8 % [44/343]; tapentadol ER,
20.0 % [72/360]), such as dizziness and somnolence
(Table 4).
Serious TEAEs were reported for 1.9 % of patients
(20/1,040) during the open-label titration period, and for
3.5 % of patients (12/343) in the placebo group and 5.0 %
of patients (18/360) in the tapentadol ER group during the
double-blind maintenance period. The majority of serious
TEAEs were reported for no more than one patient during
the open-label titration period or double-blind maintenance
period. The only serious TEAEs reported for more than one
patient during the open-label titration period were chest
pain (0.5 % [5/1,040]) and dehydration (0.2 % [2/1,040]).
During the double-blind maintenance period, the only
serious TEAEs reported for more than one patient in either
treatment group were dehydration (placebo, 0 %; tapent-
adol ER, 0.6 % [2/360]) and coronary artery disease (pla-
cebo, 0.6 % [2/343]; tapentadol ER, 0 %).
The mean (SD) change in HbA1c levels was -0.12
(0.467) from the start of the open-label titration period to
endpoint of the open-label titration period. Mean (SD)
changes in HbA1c levels from the start of the open-label
titration period to endpoint of the double-blind mainte-
nance period were 0.11 (1.040) for patients in the placebo
group and -0.13 (1.009) for patients in the tapentadol ER
group.
4 Discussion
For this analysis, efficacy and selected safety data were
pooled from two randomized-withdrawal, placebo-
controlled, phase 3 studies of similar design in patients
with moderate to severe, chronic, painful DPN [18, 19].
Results of this pooled analysis support those of the two
individual studies [18, 19] and indicate that treatment with
tapentadol ER (100–250 mg bid) is associated with clini-
cally meaningful reductions in pain intensity during the
titration period. Improvements in pain intensity achieved
during the open-label titration period for patients who
achieved at least a 1-point reduction in pain intensity and
tolerated tapentadol ER treatment were maintained for
patients who continued taking tapentadol ER, while pain
intensity increased for patients who switched to placebo. A
significant difference, in favour of tapentadol ER, was
observed between the tapentadol ER and placebo groups in
the mean change from baseline to week 12 of the double-
blind maintenance period. Sensitivity analyses using
alternative imputation methods supported the results of the
primary analysis, showing significant differences between
the tapentadol ER and placebo groups in the mean change
from baseline to week 12 of the double-blind maintenance
period. Changes in HbA1c levels over the course of the two
pooled studies were minimal, suggesting that tapentadol
ER treatment had no relevant impact on glycaemic control,
and that the improvements in pain intensity observed with
tapentadol ER treatment observed in the current analysis
were not likely related to changes in glycaemic control.
The therapeutic dose range of tapentadol ER (100–250 mg
bid) was well tolerated and effective when patients were
individually titrated to their optimal dose (median modal
total daily dose during titration, 300 mg; median modal
total daily dose during maintenance, 400 mg).
In addition to the positive results observed for the pri-
mary efficacy endpoint, patients who received tapentadol
ER achieved clinically meaningful improvements in pain
intensity and health status, based on responder rate analy-
ses and the PGIC, respectively. More than 50 % of patients
who received tapentadol ER throughout the study achieved
a clinically meaningful 30 % improvement in pain inten-
sity [23] from the start of titration to the end of the
maintenance period, and approximately 39 % achieved a
50 % improvement in pain intensity. On the PGIC, more
than 60 % of patients reported clinically meaningful
improvements (‘‘very much improved’’ or ‘‘much
improved’’ [23]) in their health status over 15 weeks of
continuous tapentadol ER treatment.
Painful DPN is often associated with a substantial neg-
ative impact on patients’ physical function, mental and
emotional well-being, social interactions and overall
quality of life [27–29]. For that reason, improvements in
Table 4 Treatment-emergent adverse events (TEAEs) reported by
C5 % of patients in either treatment group during the double-blind
(DB) maintenance period (DB safety population)a




Gastrointestinal disorders 61 (17.8) 125 (34.7)
Nausea 27 (7.9) 61 (16.9)
Vomiting 9 (2.6) 34 (9.4)
Diarrhoea 18 (5.2) 27 (7.5)
Constipation 2 (0.6) 21 (5.8)
Nervous system disorders 44 (12.8) 72 (20.0)
Dizziness 6 (1.7) 27 (7.5)
Somnolence 1 (0.3) 17 (4.7)
Headache 18 (5.2) 14 (3.9)
Psychiatric disorders 31 (9.0) 55 (15.3)
Anxiety 15 (4.4) 26 (7.2)
Insomnia 11 (3.2) 19 (5.3)
Musculoskeletal and connective tissue
disorders
44 (12.8) 46 (12.8)
Myalgia 15 (4.4) 18 (5.0)
ER extended release
a Incidence is based on the number of patients experiencing C1
TEAE, not the number of TEAEs
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quality of life and physical function, as well as reductions
in pain, have been established as a goal of therapy for
painful DPN [7, 30]. In their evidence-based guidelines, the
American Academy of Neurology, the American Associa-
tion of Neuromuscular and Electrodiagnostic Medicine,
and the American Academy of Physical Medicine noted
that evidence for improvements in quality of life and
physical function is lacking for a number of treatments for
painful DPN [7]. Results of the current pooled analysis
showed that tapentadol ER treatment was associated with
significant improvements in health-related quality of life
and physical functioning compared with placebo, based on
differences in the mean change from the start to the end of
the double-blind treatment period in the SF-36 physical
functioning, role-physical, bodily pain, social functioning
and role-emotional subscale scores; the SF-36 physical
component summary score; and the EQ-5D health status
index score. One of the available treatment options for
painful DPN, pregabalin [7], has been shown to provide
improvements in measures of sleep quality, as well as
quality of life [31]. Results of separate phase 3b studies in
patients with severe, chronic low back pain with or without
a neuropathic pain component, as diagnosed using the
painDETECT questionnaire, showed that tapentadol ER
(50–250 mg bid) was associated with improvements from
baseline in measures of anxiety [32, 33], depression [32,
33] and sleep quality [32, 33]. Further research is needed to
support the efficacy of tapentadol ER for improving these
outcomes in patients with painful DPN.
Pooling of efficacy data from the individual phase 3
studies [18, 19] of tapentadol ER for the management of
painful DPN allowed for the evaluation of the effects of
patient-specific factors on the efficacy of tapentadol ER.
Slight numerical differences were observed in the differ-
ence in the mean change in pain intensity from baseline to
week 12 of the maintenance period between the placebo
and tapentadol ER groups for all subgroup analyses, but
these differences were not considered to be clinically rel-
evant. Tapentadol ER was effective for the management of
moderate to severe, chronic, painful DPN across all ana-
lysed subgroups.
Opioid analgesics provide relief for neuropathic pain,
including painful DPN, but poor tolerability, particularly
gastrointestinal tolerability, may hinder their use [2, 7, 8].
In the current pooled analysis, tapentadol ER (100–250 mg
bid) was shown to be well tolerated on the basis of the
incidences of TEAEs and low incidence of discontinua-
tions due to adverse events; the side effect profile in the
current analysis was consistent with that observed in pre-
vious studies of tapentadol ER for the management of
chronic pain [12–14, 20]. The two studies [18, 19] in this
pooled analysis included no active comparator; however,
results from previous phase 3 studies comparing tapentadol
ER and oxycodone controlled release (CR) in patients with
moderate to severe chronic osteoarthritis or low back pain
showed that tapentadol ER treatment was associated with
better gastrointestinal tolerability than oxycodone CR [12,
13, 20]. A pooled analysis [14] of results from three phase
3 studies in patients with osteoarthritis knee pain or low
back pain showed that tapentadol ER (100–250 mg bid)
provided non-inferior analgesic efficacy to oxycodone HCl
CR (20–50 mg bid) but had superior gastrointestinal tol-
erability, based on the incidences of common gastrointes-
tinal TEAEs (i.e. constipation, nausea and vomiting). The
improved tolerability of tapentadol ER compared with the
pure l-opioid agonist oxycodone CR may result from the
opioid-sparing effect engendered by the contribution of a
second mechanism of action, norepinephrine reuptake
inhibition, to its analgesic activity [11].
As a post hoc analysis of pooled data from two separate
phase 3 clinical studies [18, 19], this analysis was associ-
ated with certain inherent limitations. Although both
15-week studies [18, 19] had similar randomized-
withdrawal, double-blind, placebo-controlled designs and
included similar patient populations, there were minor
differences between the two studies that could possibly
have affected the results. The formulations of tapentadol
ER used in the two studies differed; a conventional hy-
promellose-based formulation was used in the first study
[18], while a new formulation of tapentadol ER, with a
high mechanical strength resulting from a polyethylene
oxide matrix and melt extrusion manufacturing process,
was used in the second study [19]. Bioequivalence has
generally been demonstrated for these two formulations
[21]. In addition, the enrolment criteria related to glycae-
mic control differed in the two studies. In the first study
[18], patients were required to have HbA1c levels of no
more than 11 % for at least 3 months prior to enrolment; in
the second study [19], patients were required to have a
stable, optimized diabetic regimen for at least 3 months
prior to enrolment. The pre-specified washout time periods
also differed between the two studies (3–14 days in the first
study [18] and 5 days in the second study [19]); however,
the duration of the washout period was flexible to accom-
modate the washout of drugs with longer elimination half-
lives. Despite these differences in study design, efficacy
and tolerability results were generally comparable across
the two individual phase 3 studies [18, 19] and the current
pooled analysis. Furthermore, these trials formed the basis
for the approval in the United States of tapentadol ER for
the management of neuropathic pain associated with DPN
in adults severe enough to require daily, around-the-clock,
long-term opioid treatment and for whom alternative
treatment options are inadequate [34].
The degree of enrichment, based on the requirement that
patients responded to tapentadol ER with at least a 1-point
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improvement in pain intensity during the open-label titra-
tion period, was relatively small in the current study.
Therefore, these results should at least be generalizable to
the population of patients who can tolerate treatment with
tapentadol ER.
5 Conclusion
Results of this pooled analysis support the efficacy of ta-
pentadol ER (100–250 mg bid) for the management of
neuropathic pain associated with DPN in adults, which was
previously demonstrated in two individual phase 3 studies
[18, 19]. In addition, tapentadol ER was shown to provide
consistent efficacy, regardless of race, sex, age, prior opi-
oid experience or pain intensity at the start of the double-
blind maintenance period. This analysis also provided
evidence for the positive impact of tapentadol ER on
health-related quality of life and physical functioning in
patients with painful DPN, which may be of particular
relevance because patients with DPN often experience a
decline in physical functioning and quality of life [2–5]. In
addition to pain intensity and quality of life, the effects of
treatment on other comorbidities of painful DPN (e.g.
anxiety, depression and insomnia) should be considered
[6].
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